Morphogen-IX has developed protein-engineered forms of bone morphogenetic protein 9 (BMP9), conferring potent protection of the blood vessels in the lung, whilst lacking the bone-inducing properties of the native protein. BMP9 has shown strong preclinical efficacy in the reversal of PAH. This approach is based on targeting the central pathway underlying PAH identified in human … Continue reading Morphogen-IX – Nick Morell
News
According to the US Food and Drug Association, Breakthrough therapy designation is intended to expedite the development and review of drugs for serious or life-threatening conditions. The criteria for breakthrough therapy designation require preliminary clinical evidence that demonstrates the drug may have substantial improvement on at least one clinically significant endpoint over available therapy. The … Continue reading Acceleron’s Sotatercept – Granted FDA’s Breakthrough Therapy Status for PAH.
On the 5th May 2020, Our Founder and Chairman Jamie Strachan spoke with Stephanie Barwick, Chief Executive Officer PVRI. To watch the full interview please click here. Thank you to the PVRI for allowing us to share the video. https://vimeo.com/414818134